Form 4: Nuvalent CFO Sells Shares Under 10b5-1 Plan

Nuvalent's Chief Financial Officer, Alexandra Balcom, executed a series of stock transactions under a pre-arranged trading plan.

Summary

• Alexandra Balcom, Chief Financial Officer of Nuvalent, Inc., reported transactions involving Class A Common Stock.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on December 23, 2025.
• Balcom acquired 5,384 shares at $6.89 and 6,046 shares at $18.93.
• Additionally, 11,430 shares were disposed of at a weighted average price of $123.58, with individual sales ranging from $123.51 to $123.62.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant sale of shares by the CFO, despite being executed under a 10b5-1 plan.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially less market-sensitive trading.
• The CFO acquired shares at lower price points, potentially indicating a belief in future value appreciation.

Negatives

• A significant number of shares were sold by a key executive, which could be perceived negatively by the market.
• The sale of 11,430 shares at a high price point ($123.58 weighted average) represents a substantial divestment.

Risks

• The sale of a large number of shares by the CFO could signal a lack of confidence in near-term stock performance, although executed under a 10b5-1 plan.
• The weighted average sale price indicates a series of transactions, potentially impacting market liquidity if executed rapidly.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The transactions are historical events executed under a pre-defined plan.

Management Comments

• The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common event for executives looking to diversify or manage personal finances. However, the scale of the sale by a CFO warrants attention, especially in the biopharmaceutical sector where stock performance is often closely tied to clinical trial progress and regulatory approvals.

Stakeholder Impact

• Shareholders: May interpret the CFO's sale as a potential negative signal, although the 10b5-1 plan mitigates concerns about opportunistic trading.
• Employees: May also view the sale with caution, potentially impacting morale if it suggests a lack of confidence from leadership.
• Creditors/Suppliers: Unlikely to be directly impacted by this specific transaction.

Next Steps

• The reporting person may be requested to provide further details on the specific prices of the shares sold.

Key Dates

Recommendation

The filing reports insider selling under a pre-arranged plan, which is a common practice. While the sale of a significant number of shares by the CFO could be a concern, the 10b5-1 plan suggests it was pre-scheduled and not based on immediate non-public information. Without further context on the company's performance or future catalysts, a 'hold' recommendation is prudent, allowing investors to monitor the company's ongoing operations and strategic developments.

Keywords

Nuvalent, NUVL, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Alexandra Balcom, Chief Financial Officer, Class A Common Stock, Beneficial Ownership